Search
News & Events
Bushfires: Tips to protect family from smoke exposurePerth’s north-east is under threat from an out-of-control bushfire.
News & Events
Enhancing the lung health for preterm birth survivors by uncovering treatable traitsA project to uncover treatable traits to improve the lung health of people born preterm has been made possible thanks to a $1.99 million Medical Research Future Fund (MRFF) grant.
News & Events
Community partnership sets priorities for preterm lung health researchRespiratory disease remains one of the most significant complications of preterm birth, with lasting consequences.
News & Events
New funding to accelerate AI personalised phage therapiesWal-yan researchers have been awarded $500,000 for their innovative research, supported by the Western Australian Government’s Future Health Medical Research and Innovation (FHRI) Fund.
Research
Antenatal creatine supplementation reduces persistent fetal lung inflammation and oxidative stress in an ovine model of chorioamnionitisChorioamnionitis is a common antecedent of preterm birth and induces inflammation and oxidative stress in the fetal lungs. Reducing inflammation and oxidative stress in the fetal lungs may improve respiratory outcomes in preterm infants. Creatine is an organic acid with known anti-inflammatory and antioxidant properties.
Research
Lung structural and functional impairments in young children with cystic fibrosis diagnosed following newborn screening – A nationwide observational studyNon-invasive and sensitive clinical endpoints are needed to monitor onset and progression of early lung disease in children with cystic fibrosis (CF). We compared lung clearance index (LCI), FEV1, functional and structural lung magnetic resonance imaging (MRI) outcomes in Swiss children with CF diagnosed following newborn screening.
Research
Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trialBronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults.
Research
Current and novel therapies for management of Acinetobacter baumannii-associated pneumoniaAcinetobacter baumannii is a common pathogen associated with hospital-acquired pneumonia showing increased resistance to carbapenem and colistin antibiotics nowadays. Infections with A. baumannii cause high patient fatalities due to their capability to evade current antimicrobial therapies, emphasizing the urgency of developing viable therapeutics to treat A. baumannii-associated pneumonia.
Research
From Local to Systemic: The Journey of Tick Bite Biomarkers in Australian PatientsTick bites and tick-related diseases are on the rise. Diagnostic tests that identify well-characterised tick-borne pathogens (TBPs) possess limited capacity to address the causation of symptoms associated with poorly characterised tick-related illnesses, such as debilitating symptom complexes attributed to ticks (DSCATT) in Australia. Identification of local signals in tick-bitten skin that can be detected systemically in blood would have both clinical (diagnostic or prognostic) and research (mechanistic insight) utility, as a blood sample is more readily obtainable than tissue biopsies.
Research
tesG expression as a potential clinical biomarker for chronic Pseudomonas aeruginosa pulmonary biofilm infectionsPseudomonas aeruginosa infections in the lungs affect millions of children and adults worldwide. To our knowledge, no clinically validated prognostic biomarkers for chronic pulmonary P. aeruginosa infections exist. Therefore, this study aims to identify potential prognostic markers for chronic P. aeruginosa biofilm lung infections.